Literature DB >> 21365628

Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online.

Sharlene Gill1, Charles Loprinzi, Hagen Kennecke, Axel Grothey, Garth Nelson, Ryan Woods, Caroline Speers, Steven R Alberts, Aditya Bardia, Michael J O'Connell, Daniel J Sargent.   

Abstract

BACKGROUND: Numeracy and Adjuvant! are 2 web-based calculators that are used widely to estimate the prognosis and potential benefit of adjuvant 5-fluorouracil (5-FU)-based therapy for patients with stage II and III colon cancer. In this study, the authors compared the predicted survival estimates from these models with the actual observed estimates in independent datasets that were derived from a population cohort and from clinical trials.
METHODS: The population cohort was derived from the British Columbia Colorectal Cancer Outcomes Unit database, which identified referred patients with stage II and III colon cancer from 1995 to 1996 and from 1999 to 2003. Patients who were enrolled in North Central Cancer Trials Group (NCCTG) trials NCCTG 94651 and NCCTG 914653 were included in the trials dataset. Patient and disease data were used to predict 5-year relapse-free and overall survival using both tools.
RESULTS: In the population-based dataset (N = 2033), Adjuvant! offered more reliable predictions of prognosis for patients who underwent surgery alone, but it had reliability similar to that of Numeracy for predicting the prognosis for patients who received adjuvant 5-FU. Both models tended to overestimate survival for patients with stage II disease who received 5-FU. In the trials dataset of patients who underwent and received 5-FU (N = 1729), Numeracy and Adjuvant! demonstrated similar performance and improved correctness.
CONCLUSIONS: This independent validation analysis demonstrated that both Numeracy and Adjuvant! had similar predictive performance and acceptable reliability for patients with stage III disease. Survival outcomes of patients with stage II colon cancer who received adjuvant 5-FU were slightly lower than estimated by either model.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21365628      PMCID: PMC3111760          DOI: 10.1002/cncr.26003

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators.

Authors:  Aditya Bardia; Charles Loprinzi; Axel Grothey; Garth Nelson; Steven Alberts; Smitha Menon; Stephan Thome; Sharlene Gill; Dan Sargent
Journal:  Semin Oncol       Date:  2010-02       Impact factor: 4.929

2.  Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer.

Authors:  Michael J O'Connell; Daniel J Sargent; Harold E Windschitl; Lois Shepherd; Michelle R Mahoney; James E Krook; Sandra Rayson; Roscoe F Morton; Kendrith M Rowland; John W Kugler
Journal:  Clin Colorectal Cancer       Date:  2006-07       Impact factor: 4.481

3.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

Authors:  Gershon Y Locker; Stanley Hamilton; Jules Harris; John M Jessup; Nancy Kemeny; John S Macdonald; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2006-10-23       Impact factor: 44.544

4.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Authors:  Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Greg J Davis; Stephen K Chia; Karen A Gelmon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

5.  Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.

Authors:  M J O'Connell; J A Laurie; M Kahn; R J Fitzgibbons; C Erlichman; L Shepherd; C G Moertel; W I Kocha; R Pazdur; H S Wieand; J Rubin; A M Vukov; J H Donohue; J E Krook; A Figueredo
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Authors:  J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

7.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer?

Authors:  C L Loprinzi; P M Ravdin; M de Laurentiis; P Novotny
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Authors:  Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

  10 in total
  13 in total

1.  Patterns of surveillance following curative intent therapy for gastroesophageal cancer.

Authors:  Renata D Peixoto; Howard J Lim; Haerin Kim; Ahmad Abdullah; Winson Y Cheung
Journal:  J Gastrointest Cancer       Date:  2014-09

2.  Counterpoint: sowing the seeds of standardized care to reap better patient outcomes.

Authors:  Joseph O Jacobson
Journal:  J Oncol Pract       Date:  2012-05-29       Impact factor: 3.840

Review 3.  Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era.

Authors:  Patrick G Johnston
Journal:  Oncologist       Date:  2014-04-09

4.  ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Authors:  Lindsay A Renfro; Axel Grothey; Yuan Xue; Leonard B Saltz; Thierry André; Chris Twelves; Roberto Labianca; Carmen J Allegra; Steven R Alberts; Charles L Loprinzi; Greg Yothers; Daniel J Sargent
Journal:  J Natl Cancer Inst       Date:  2014-10-29       Impact factor: 13.506

5.  Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).

Authors:  En Cheng; Fang-Shu Ou; Chao Ma; Donna Spiegelman; Sui Zhang; Xin Zhou; Tiffany M Bainter; Leonard B Saltz; Donna Niedzwiecki; Robert J Mayer; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Edward L Giovannucci; Erin L Van Blarigan; Justin C Brown; Kimmie Ng; Cary P Gross; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2022-01-07       Impact factor: 44.544

6.  Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

Authors:  Demetris Papamichael; Lindsay A Renfro; Christiana Matthaiou; Greg Yothers; Leonard Saltz; Katherine A Guthrie; Eric Van Cutsem; Hans-Joachim Schmoll; Roberto Labianca; Thierry André; Michael O'Connell; Steven R Alberts; Daniel G Haller; Panteleimon Kountourakis; Daniel J Sargent
Journal:  J Geriatr Oncol       Date:  2016-07-25       Impact factor: 3.599

7.  TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.

Authors:  Benjamin C Chandler; Leah Moubadder; Cassandra L Ritter; Meilan Liu; Meleah Cameron; Kari Wilder-Romans; Amanda Zhang; Andrea M Pesch; Anna R Michmerhuizen; Nicole Hirsh; Marlie Androsiglio; Tanner Ward; Eric Olsen; Yashar S Niknafs; Sofia Merajver; Dafydd G Thomas; Powel H Brown; Theodore S Lawrence; Shyam Nyati; Lori J Pierce; Arul Chinnaiyan; Corey Speers
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 8.  Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.

Authors:  Alyson L Mahar; Carolyn Compton; Susan Halabi; Kenneth R Hess; Martin R Weiser; Patti A Groome
Journal:  J Surg Oncol       Date:  2017-08-02       Impact factor: 3.454

9.  Stage II-III colon cancer: a comparison of survival calculators.

Authors:  Riccardo Lemini; Kristopher Attwood; Stacey Pecenka; Juliet Grego; Aaron C Spaulding; Steven Nurkin; Dorin T Colibaseanu; Emmanuel Gabriel
Journal:  J Gastrointest Oncol       Date:  2018-12

10.  Differences in Liver Parenchyma are Measurable with CT Radiomics at Initial Colon Resection in Patients that Develop Hepatic Metastases from Stage II/III Colon Cancer.

Authors:  John M Creasy; Kristen M Cunanan; Jayasree Chakraborty; John C McAuliffe; Joanne Chou; Mithat Gonen; Victoria S Kingham; Martin R Weiser; Vinod P Balachandran; Jeffrey A Drebin; T Peter Kingham; William R Jarnagin; Michael I D'Angelica; Richard K G Do; Amber L Simpson
Journal:  Ann Surg Oncol       Date:  2020-09-20       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.